InvestorsHub Logo
Followers 19
Posts 1039
Boards Moderated 0
Alias Born 04/18/2018

Re: None

Wednesday, 05/06/2020 2:57:40 PM

Wednesday, May 06, 2020 2:57:40 PM

Post# of 35961
This is why MedicNova chose Mipsagargin to be included in the updated patent application for its clinical trial for brain cancer.

"Initial indications that mipsagargin is well-tolerated and has some activity in glioblastoma are encouraging," said David Piccioni, M.D., Ph.D. at UC San Diego. "We look forward to expanding on this research and potentially bringing about an important new therapy for people with this aggressive disease."